Free Trial
NASDAQ:SNOA

Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis

Sonoma Pharmaceuticals logo
$3.59 +0.01 (+0.28%)
Closing price 07/18/2025 03:46 PM Eastern
Extended Trading
$3.54 -0.05 (-1.53%)
As of 07/18/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sonoma Pharmaceuticals Stock (NASDAQ:SNOA)

Key Stats

Today's Range
$3.50
$3.70
50-Day Range
$2.85
$3.94
52-Week Range
$1.75
$8.62
Volume
43,347 shs
Average Volume
798,959 shs
Market Capitalization
$5.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sonoma Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
16th Percentile Overall Score

SNOA MarketRank™: 

Sonoma Pharmaceuticals scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Sonoma Pharmaceuticals.

  • Earnings Growth

    Earnings for Sonoma Pharmaceuticals are expected to decrease in the coming year, from ($0.67) to ($1.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sonoma Pharmaceuticals is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sonoma Pharmaceuticals is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sonoma Pharmaceuticals has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Sonoma Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.78% of the float of Sonoma Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Sonoma Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sonoma Pharmaceuticals has recently decreased by 37.31%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Sonoma Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Sonoma Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.78% of the float of Sonoma Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Sonoma Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sonoma Pharmaceuticals has recently decreased by 37.31%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Sonoma Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • Search Interest

    2 people have searched for SNOA on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sonoma Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.90% of the stock of Sonoma Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 1.95% of the stock of Sonoma Pharmaceuticals is held by institutions.

  • Read more about Sonoma Pharmaceuticals' insider trading history.
Receive SNOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNOA Stock News Headlines

Trump’s Exec Order #14154 could be a “Millionaire-Maker”
Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape.
Sonoma Pharmaceuticals expands into UK market
See More Headlines

SNOA Stock Analysis - Frequently Asked Questions

Sonoma Pharmaceuticals' stock was trading at $2.69 at the beginning of the year. Since then, SNOA shares have increased by 33.5% and is now trading at $3.59.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) released its quarterly earnings data on Tuesday, June, 17th. The company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.58. The firm had revenue of $3.75 million for the quarter, compared to the consensus estimate of $4.44 million. Sonoma Pharmaceuticals had a negative trailing twelve-month return on equity of 58.73% and a negative net margin of 24.23%.

Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Meta Platforms (META), NVIDIA (NVDA), Bristol Myers Squibb (BMY), Advanced Micro Devices (AMD), Ford Motor (F) and PayPal (PYPL).

Company Calendar

Last Earnings
6/17/2025
Today
7/18/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SNOA
CIK
1367083
Employees
180
Year Founded
1999

Profitability

EPS (Trailing Twelve Months)
($3.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.46 million
Net Margins
-24.23%
Pretax Margin
-20.35%
Return on Equity
-58.73%
Return on Assets
-21.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.09
Quick Ratio
2.38

Sales & Book Value

Annual Sales
$14.29 million
Price / Sales
0.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.73 per share
Price / Book
1.33

Miscellaneous

Outstanding Shares
1,640,000
Free Float
1,579,000
Market Cap
$5.95 million
Optionable
Not Optionable
Beta
1.33

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:SNOA) was last updated on 7/19/2025 by MarketBeat.com Staff
From Our Partners